Trial Profile
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary)
- Indications Lung cancer; Malignant-mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer
- Focus Diagnostic use
- 06 May 2016 New trial record